Market Access Part Two: Navigating the complexities of global market acces... The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.
Views & Analysis Effective decision making in early asset development and com... Addressing the data and evidence gap in the early stages of asset development.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.